Non-exclusive rebate agreement for Octreotide long-acting depot injections
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Octreotid (ATC-Code nach WHO: H01CB02)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No guaranteed purchase volumes; actual demand depends on physician prescribing behavior, patient numbers, and pharmacy...
The buyer may terminate the open-house procedure early if exclusive rebate agreements are concluded, which typically oc...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- May 31, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2028
- Non-exclusive rebate agreement for Octreotide (ATC H01CB02) long-acting depot injections
- Open-house model with continuous participation until 31 May 2028
Show full summary
This is an Open-House model for non-exclusive rebate agreements under §130a(8) SGB V for Octreotide (ATC H01CB02) long-acting depot injections. The buyer is AOK PLUS. There is no guaranteed volume, no estimated value, and no exclusivity. The procedure is open to all qualified pharmaceutical companies continuously until 31 May 2028, with the first submission deadline on 30 April 2026. The notice explicitly states it is not a public procurement under EU directive.
Risks
No guaranteed purchase volumes; actual demand depends on physician prescribing behavior, patient numbers, and pharmacy...
The buyer may terminate the open-house procedure early if exclusive rebate agreements are concluded, which typically oc...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company under §4(18) AMG for the offered product
Eligibility
- Declaration of no exclusion grounds (§§123,124 GWB)
Administrative
- Declaration regarding Russia sanctions (EU Regulation 833/2014)
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive rebate agreement for Octreotide long-acting depot injections
Open-house model for non-exclusive rebate agreements on Octreotide (ATC H01CB02) limited to long-acting depot forms for injection. No minimum quantities, no exclusivity, continuous participation until 31 May 2028.
Location
Duration
Category
Award Criteria
Deadline
Award details
No award criteria specified. The procedure is an open-house model with no competitive award
all eligible participants can conclude a rebate agreement.
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Octreotid (ATC-Code nach WHO: H01CB02)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 29 Mar 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 214696-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No guaranteed purchase volumes; actual demand depends on physician prescribing behavior, patient numbers, and pharmacy...
The buyer may terminate the open-house procedure early if exclusive rebate agreements are concluded, which typically oc...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications